Title:
ADENOSINE COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT OR STEREOISOMERIDE THEREOF, AND USE
Document Type and Number:
WIPO Patent Application WO/2020/253866
Kind Code:
A1
Abstract:
The present invention relates to a compound represented by formula I or a pharmaceutically acceptable salt, stereoisomeride, pharmaceutically acceptable hydrate or solvate, or pharmaceutically acceptable ester thereof, wherein R is selected from heteroaryl, substituted heteroaryl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, alkyl, and substituted alkyl, and the substitutions each refer to an independent substitution by one or more hydroxyalkylene groups. The compound or the pharmaceutically acceptable salt, stereoisomeride, pharmaceutically acceptable hydrate or solvate, or pharmaceutically acceptable ester thereof in the present invention has activation activity for an A2A adenosine receptor, can improve the permeability of a blood-brain barrier to facilitate drug delivery across the blood-brain barrier, and can also prevent or treat A2A adenosine receptor activation activity-related diseases.
Inventors:
ZHONG WU (CN)
ZHANG MIN (CN)
ZHOU XINBO (CN)
FAN SHIYONG (CN)
LI SONG (CN)
ZHANG MIN (CN)
ZHOU XINBO (CN)
FAN SHIYONG (CN)
LI SONG (CN)
Application Number:
PCT/CN2020/097392
Publication Date:
December 24, 2020
Filing Date:
June 22, 2020
Export Citation:
Assignee:
ACAD OF MILITARY MEDICAL SCIENCES (CN)
International Classes:
A61P9/08; A61K31/52; A61P9/10; A61P37/00; C07H19/167
Foreign References:
| CN103221535A | 2013-07-24 | |||
| CN109125728A | 2019-01-04 | |||
| US20190083497A1 | 2019-03-21 | |||
| CN200580033215A | 2005-08-02 |
Other References:
JACKSON, S.ET AL.: "The effect of regadenoson on the integrity of the human blood-brain barrier, a pilot study", JOURNAL OF NEURO-ONCOLOGY, vol. 132, no. 3, 31 May 2017 (2017-05-31), pages 513 - 519, XP036262454, ISSN: 0167-594X, DOI: 20200907124955A
CHANG CAN-CAN;ZHOU JUN;YANG BEN-QIANG;LI HONG-YI;XU ZHI-HUA;LIN SEN;DUAN YANG: "Preliminary study on assessment of regadenoson-induced blood-brain barrier opening by MR perfusion weighted imaging", JOURNAL OF CHINA CLINIC MEDICAL IMAGING, vol. 27, no. 10, 20 October 2016 (2016-10-20), pages 690 - 693, XP055884594, ISSN: 1008-1062
HUBER J D ET AL., TRENDS NEUROSCI, vol. 24, no. 12, 2001, pages 719 - 25
CARMAN A J ET AL., J NEUROSCI, vol. 31, no. 37, 2011, pages 13272 - 80
SOHAIL MA ET AL., HEPATOLOGY, vol. 49, no. 1, 2009, pages 185 - 94
DE LERA RUIZ M, J MED CHEM, vol. 57, no. 9, 2014, pages 3623 - 50
VARANI K, FASEB J, vol. 24, no. 4, 2010, pages 1192 - 204
HASKO G, NAT REV DRUG DISCOV, vol. 7, no. 9, 2008, pages 759 - 70
AKKARI R ET AL., CURR TOP MED CHEM, vol. 6, no. 13, 2006, pages 1375 - 99
BOSCH MP ET AL., J MED CHEM, vol. 47, no. 16, 2004, pages 4041 - 53
MULLER CE, BIOCHIM BIOPHYS ACTA, vol. 1808, no. 5, 2011, pages 1290 - 308
RIVERA-OLIVER M, LIFE SCI, vol. 101, 2014, pages 1 - 9
CHANG CAN-CAN;ZHOU JUN;YANG BEN-QIANG;LI HONG-YI;XU ZHI-HUA;LIN SEN;DUAN YANG: "Preliminary study on assessment of regadenoson-induced blood-brain barrier opening by MR perfusion weighted imaging", JOURNAL OF CHINA CLINIC MEDICAL IMAGING, vol. 27, no. 10, 20 October 2016 (2016-10-20), pages 690 - 693, XP055884594, ISSN: 1008-1062
HUBER J D ET AL., TRENDS NEUROSCI, vol. 24, no. 12, 2001, pages 719 - 25
CARMAN A J ET AL., J NEUROSCI, vol. 31, no. 37, 2011, pages 13272 - 80
SOHAIL MA ET AL., HEPATOLOGY, vol. 49, no. 1, 2009, pages 185 - 94
DE LERA RUIZ M, J MED CHEM, vol. 57, no. 9, 2014, pages 3623 - 50
VARANI K, FASEB J, vol. 24, no. 4, 2010, pages 1192 - 204
HASKO G, NAT REV DRUG DISCOV, vol. 7, no. 9, 2008, pages 759 - 70
AKKARI R ET AL., CURR TOP MED CHEM, vol. 6, no. 13, 2006, pages 1375 - 99
BOSCH MP ET AL., J MED CHEM, vol. 47, no. 16, 2004, pages 4041 - 53
MULLER CE, BIOCHIM BIOPHYS ACTA, vol. 1808, no. 5, 2011, pages 1290 - 308
RIVERA-OLIVER M, LIFE SCI, vol. 101, 2014, pages 1 - 9
Attorney, Agent or Firm:
CCPIT PATENT AND TRADEMARK LAW OFFICE (CN)
Download PDF: